Literature DB >> 11120982

Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.

J M Rolain1, M Maurin, D Raoult.   

Abstract

The in vitro activity of moxifloxacin against Coxiella burnetii was compared to those of pefloxacin, ofloxacin, and doxycycline. MICs of moxifloxacin ranged from 0.5 to 1 microg/ml for the Nine Mile, Priscilla, and Q212 strains. Moxifloxacin was not bactericidal against C. burnetii at 4 microg/ml.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11120982      PMCID： PMC90277          DOI： 10.1128/AAC.45.1.301-302.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.

Authors:  A Soman; D Honeybourne; J Andrews; G Jevons; R Wise
Journal:  J Antimicrob Chemother       Date:  1999-12       Impact factor: 5.790

2.  Bacteriostatic and bactericidal activity of levofloxacin against Rickettsia rickettsii, Rickettsia conorii, 'Israeli spotted fever group rickettsia' and Coxiella burnetii.

Authors:  M Maurin; D Raoult
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

3.  Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm.

Authors:  M Maurin; A M Benoliel; P Bongrand; D Raoult
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

4.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

5.  Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii.

Authors:  D Raoult; H Torres; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells.

Authors:  D Raoult; M Drancourt; G Vestris
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

7.  The inhibitory effect of fluoroquinolones on Coxiella burnetii growth in in-vitro systems.

Authors:  G Keren; A Keysary; R Goldwasser; E Rubinstein
Journal:  J Antimicrob Chemother       Date:  1994-06       Impact factor: 5.790

Review 8.  Q fever.

Authors:  M Maurin; D Raoult
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

9.  Q fever is absent from New Zealand.

Authors:  F Hilbink; M Penrose; E Kovacova; J Kazar
Journal:  Int J Epidemiol       Date:  1993-10       Impact factor: 7.196

10.  Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases.

Authors:  H Tissot Dupont; D Raoult; P Brouqui; F Janbon; D Peyramond; P J Weiller; C Chicheportiche; M Nezri; R Poirier
Journal:  Am J Med       Date:  1992-10       Impact factor: 4.965
View more
  7 in total

1.  Pentamidine inhibits Coxiella burnetii growth and 23S rRNA intron splicing in vitro.

Authors:  Michael F Minnick; Linda D Hicks; James M Battisti; Rahul Raghavan
Journal:  Int J Antimicrob Agents       Date:  2010-10       Impact factor: 5.283

Review 2.  Antimicrobial therapies for Q fever.

Authors:  Gilbert J Kersh
Journal:  Expert Rev Anti Infect Ther       Date:  2013-09-27       Impact factor: 5.091

3.  Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.

Authors:  Jean-Marc Rolain; Areen Boulos; Marie-Noëlle Mallet; Didier Raoult
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.

Authors:  Ioanna Spyridaki; Anna Psaroulaki; Iosif Vranakis; Yannis Tselentis; Achilleas Gikas
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

5.  Emergence of q Fever.

Authors:  E Angelakis; D Raoult
Journal:  Iran J Public Health       Date:  2011-09-30       Impact factor: 1.429

6.  Doxycycline desensitization in chronic Q fever-A critical tool for the clinician.

Authors:  Aila Luise Caplunik-Pratsch; Israel Potasman; Aharon Kessel; Alona Paz
Journal:  IDCases       Date:  2018-02-20

7.  Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells.

Authors:  Marissa S Fullerton; Punsiri M Colonne; Amanda L Dragan; Katelynn R Brann; Richard C Kurten; Daniel E Voth
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.